Publications by authors named "K Na-Bangchang"

Article Synopsis
  • A recent phase 2A study showed that Atractylodes lancea (AL) significantly reduces tumor progression and mortality in patients with advanced-stage intrahepatic cholangiocarcinoma (iCCA) when administered in doses between 1,000 to 2,000 mg.
  • The study developed a population pharmacokinetic (pop-PK) model to simulate and evaluate different dosage regimens, ultimately recommending a once-daily dose of 2,500 mg for further phase 2B studies.
  • The findings suggest that this pop-PK model can effectively predict dosages and improve clinical study outcomes, potentially minimizing drug development failures.
View Article and Find Full Text PDF

Chronic kidney disease (CKD) is a progressive condition that affects more than 10% of the world's population. Monitoring urine albumin-to-creatinine ratio (uACR) has become the gold standard for nephropathy diagnosis and control. The objective of the present study was to develop a simple, accurate, sensitive, and rapid point-of-care test (PoCT) device, MyACR, for uACR measurement, intended for use in community healthcare to screen for the risk and monitor the progress of CKD.

View Article and Find Full Text PDF

Cholangiocarcinoma (CCA) is a rare disease characterized by malignant cells derived from the epithelial cells of the biliary duct system. Despite extensive treatments, the prognosis for CCA remains poor, emphasizing the critical need for the development of novel treatments. Considerable attention has been directed towards innate immune effector cells, which can recognize tumor cells independently of the major histocompatibility complex, laying the foundation for the development of off-the-shelf drugs.

View Article and Find Full Text PDF

Background And Aims: Intrahepatic cholangiocarcinoma (iCCA) is a fatal biliary tract cancer with a dismal prognosis due to ineffective diagnostic tools with limited clinical utility. This study investigated peripheral blood indices and cytokine levels to diagnose iCCA.

Methods: Blood samples were collected from healthy subjects ( = 48) and patients with advanced-stage iCCA ( = 47) during a phase I and then phase II trial, respectively.

View Article and Find Full Text PDF

Background: Polymorphisms of Plasmodium falciparum chloroquine resistance transporter (pfcrt), Plasmodium falciparum multi-drug resistance 1 (pfmdr1) and Plasmodium falciparum kelch 13-propeller (pfk13) genes are accepted as valid molecular markers of quinoline antimalarials and artemisinins. This study investigated the distribution patterns of these genes in P. falciparum isolates from the areas along the Thai-Myanmar border during the two different periods of antimalarial usage in Thailand.

View Article and Find Full Text PDF